CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Obs…

Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN ...

Moleculin Biotech advances Annamycin AML Phase 3 program

Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.
The American Journal of Managed Care

The Why and When of Molecular Testing in AML

Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...

Aptose’s Tuspetinib Shows Promising Results in AML Treatment

Detailed price information for Aptose Biosciences Inc (APTOF) from The Globe and Mail including charting and trades.